Kolon TissueGene's TG-C Fails to Prove Efficacy in U.S. Phase 3 Clinical Trial
No Significant Advantage Over Placebo in Pain and Joint Function Improvement
"Analyzing Unexpectedly High Placebo Response"
Second Phase 3 Trial Results Expected in October
Kolon TissueGene’s cell and gene therapy for osteoarthritis, TG-C, failed to demonstrate efficacy in pain reduction and joint function improvement in its first Phase 3 clinical trial conducted in the United States.
On July 20, Kolon TissueGene announced that the topline results of the U.S. Phase 3 trial, TG-G 15302, showed that at 12 months, the co-primary endpoints — visual analog scale (VAS) for pain and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) — did not demonstrate statistically significant differences compared to placebo.
This trial was conducted at 27 centers across the United States, enrolling 531 patients with Kellgren-Lawrence grade 2·3 moderate knee osteoarthritis. Patients were randomized 2:1 into either the TG-C treatment group or a saline placebo group, with a single intra-articular injection, and efficacy and safety evaluated over 24 months.
At the 12-month mark, the mean reduction in VAS pain score was 38.6 points in the TG-C group and 39.1 points in the placebo group, failing to achieve statistical significance between groups. The mean total WOMAC score decreased by 26.34 points in the TG-C group and 27.57 points in the placebo group, again showing no significant difference. Although both pain and joint function improved compared to baseline in the TG-C group, the placebo group experienced a similar level of improvement, so the efficacy of TG-C compared to placebo was not proven in this clinical trial.
The company believes that a higher-than-expected placebo response may have influenced the trial results and is conducting further subgroup analyses by study site and patient population.
Kolon TissueGene stated, "For clinical trials involving diseases such as osteoarthritis that are accompanied by pain — especially when using intra-articular injection — it has been reported that a relatively high placebo response is often observed. We are thoroughly examining these related factors, as these characteristics may have influenced the results in this trial."
No safety concerns related to TG-C were observed in the topline results. The percentage of patients who required total knee replacement due to worsening osteoarthritis was lower in the TG-C group at 0.6% (2 of 310) compared to 5.3% (8 of 151) in the placebo group.
Kolon TissueGene plans to refine its future development strategy based on a detailed analysis of these trial results. As part of these efforts, the company intends to appoint orthopedic specialist Andy Weymann, who previously served as Chief Medical Officer (CMO) for 14 years at the global healthcare company Smith & Nephew, as its new CMO.
The topline results of TG-C’s second Phase 3 trial in the United States are scheduled to be announced in October. While both trials used the same protocol, they were conducted independently at different clinical sites by different investigators and with different patient populations.
Nam Moonjong, CEO of Kolon TissueGene, stated, "In this first trial, the higher-than-expected placebo response appears to have significantly affected result interpretation. We are currently conducting multifaceted and detailed analyses of various variables, including the possibility of site-specific differences identified through additional analyses."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
He added, "The second trial is not a simple repetition of the first but an independent study performed under different conditions, so we are paying close attention to the results to be announced in October."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.